

# Vincent Wai-Sun Wong

## List of Articles by Year in descending order

Source: [//exaly.com/author-pdf/8241949/publications.pdf](https://exaly.com/author-pdf/8241949/publications.pdf)

Version: 2025-02-01

518

PR articles

48,919

PR citations

1550

100

PR h-index

1792

207

g-index

613

documents

59338

doc citations

1506

109

h-index

47979

citing authors

#	ARTICLE	IF	CITATIONS
1	Interplay between gut microbiome, host genetic and epigenetic modifications in MASLD and MASLD-related hepatocellular carcinoma. <i>Gut</i> , 2025, 74, 141-152.	16.8	86
2	A machine learning model to predict liver-related outcomes after the functional cure of chronic hepatitis B. <i>Journal of Hepatology</i> , 2025, 82, 235-244.	4.2	13
3	AI-Safe-C score: Assessing liver-related event risks in patients without cirrhosis after successful direct-acting antiviral treatment. <i>Journal of Hepatology</i> , 2025, 82, 456-463.	4.2	9
4	acFibroMASH Index for the Diagnosis of Fibrotic MASH and Prediction of Liver-related Events: An International Multicenter Study. <i>Clinical Gastroenterology and Hepatology</i> , 2025, 23, 785-796.	6.0	10
5	Gamma-glutamyl transferase: A potential biomarker for pancreas steatosis in patients with concurrent obesity, insulin resistance and metabolic dysfunction-associated steatotic liver disease. <i>Clinical Obesity</i> , 2025, 15, .	1.9	1
6	Alcohol-associated hepatitis trends before and following the onset of the COVID-19 pandemic across two distinct cohorts in the United States and Hong Kong. <i>JHEP Reports</i> , 2025, 7, 101254.	4.5	2
7	A blood-based biomarker panel for non-invasive diagnosis of metabolic dysfunction-associated steatohepatitis. <i>Cell Metabolism</i> , 2025, 37, 59-68.e3.	25.2	36
8	Impact of PNPLA3	3.9	10
9	in Lean Individuals and in Cryptogenic Steatotic Liver Disease. <i>Liver International</i> , 2025, 45, . Global burden of metabolic dysfunction-associated steatotic liver disease, 2010 to 2021. <i>JHEP Reports</i> , 2025, 7, 101271.	4.5	49
10	Histological severity, clinical outcomes and impact of antiviral treatment in indeterminate phase of chronic hepatitis B: A systematic review and meta-analysis. <i>Journal of Hepatology</i> , 2025, 82, 992-1003.	4.2	12
11	A social media listening study of patients'™ experiences relating to metabolic dysfunction-associated steatotic liver disease: The LISTEN-MASLD study. <i>Annals of Hepatology</i> , 2025, 30, 101741.	1.6	5
12	Intestinal TM6SF2 protects against metabolic dysfunction-associated steatohepatitis through the gut-liver axis. <i>Nature Metabolism</i> , 2025, 7, 102-119.	17.1	14
13	What is new in the 2024 Chinese guidelines for fatty liver disease?. <i>Clinical and Molecular Hepatology</i> , 2025, 31, e239-e246.	8.9	0
14	Prognostic performance of the two-step clinical care pathway in metabolic dysfunction-associated steatotic liver disease. <i>Journal of Hepatology</i> , 2025, 83, 304-314.	4.2	22
15	Acute-on-chronic liver failure (ACLF): the "Kyoto Consensus"™ steps from Asia. <i>Hepatology International</i> , 2025, 19, 1-69.	4.2	31
16	Addressing the High and Rising Global Burden of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) and Metabolic Dysfunction-Associated Steatohepatitis (MASH): From the Growing Prevalence to Payers' Perspective. <i>Alimentary Pharmacology and Therapeutics</i> , 2025, 61, 1467-1478.	3.7	27
17	Pharmacological Treatment of Ascites: Challenges and Controversies. <i>Pharmaceuticals</i> , 2025, 18, 339.	4.2	1
18	Metabolic dysfunction-associated steatotic liver disease in adults. <i>Nature Reviews Disease Primers</i> , 2025, 11, .	47.2	115

#	ARTICLE	IF	CITATIONS
19	Impact of cardiometabolic risk factors on hepatic fibrosis and clinical outcomes in MASLD: A population-based multi-cohort study. <i>JHEP Reports</i> , 2025, 7, 101388.	4.5	5
20	Metabolic Cause of Cirrhosis Is the Emerging Etiology for Primary Liver Cancer in the Asia-Oceania Region: Analysis of Global Burden of Disease (GBD) Study 2021. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2025, 40, 1188-1201.	2.5	5
21	Global Burden of Major Chronic Liver Diseases in 2021. <i>Liver International</i> , 2025, 45, .	3.9	6
22	From "Burnt-Out" to "Burning-Out": Capturing Liver Fat Loss in Patients With Advanced Metabolic Dysfunction-Associated Steatotic Liver Disease From a Dynamic Perspective. <i>Gastroenterology</i> , 2025, 169, 326-336.e4.	0.9	10
23	The new definition of metabolic dysfunction-associated steatotic liver disease: the role of ultrasound and elastography. <i>Ultrasonography</i> , 2025, 44, 189-201.	2.1	3
24	Identification of Clinically Significant Portal Hypertension in cACLD Individuals With Spleen Stiffness Measurement. <i>Liver International</i> , 2025, 45, .	3.9	1
25	Modeling Reductions in Liver Fat: Comparing Noninvasive Tests to Magnetic Resonance Imaging "Proton Density Fat Fraction. <i>Gastro Hep Advances</i> , 2025, 4, 100669.	1.1	0
26	Global Consensus Recommendations for Metabolic Dysfunction-Associated Steatotic Liver Disease and Steatohepatitis. <i>Gastroenterology</i> , 2025, 169, 1017-1032.e2.	0.9	55
27	HTD1801 demonstrates promising potential for histologic improvements in metabolic dysfunction-associated steatohepatitis in both a preclinical and phase 2 study. <i>Clinical and Molecular Hepatology</i> , 2025, 31, 1071-1083.	8.9	2
28	Global patterns of utilization of noninvasive tests for the clinical management of metabolic dysfunction-associated steatotic liver disease. <i>Hepatology Communications</i> , 2025, 9, .	4.5	5
29	An Expert Consensus Delphi Panel in Metabolic Dysfunction- and Alcohol-associated Liver Disease: Opportunities and Challenges in Clinical Practice. <i>Clinical Gastroenterology and Hepatology</i> , 2025, 24, 633-645.e4.	6.0	10
30	Lifestyle modification programme for people living with HIV with metabolic dysfunction-associated steatotic liver disease: a randomised controlled trial. <i>Lancet HIV</i> , the, 2025, 12, e416-e427.	7.9	2
31	Long-Term Dynamic Changes of Alanine Aminotransferase Levels Are Associated With Liver-Related Events in Nucleos(t)ide Analogue-Treated Chronic Hepatitis B Patients in China. <i>Alimentary Pharmacology and Therapeutics</i> , 2025, 62, 419-429.	3.7	4
32	Intermittent fasting and metabolic dysfunction-associated steatotic liver disease: the potential role of the gut-liver axis. <i>Cell and Bioscience</i> , 2025, 15, .	5.5	2
33	A call for doubling the diagnostic rate of at-risk metabolic dysfunction-associated steatohepatitis. <i>Lancet Regional Health - Europe</i> , The, 2025, 54, 101320.	7.0	9
34	Effect of Antidiabetic Drug Classes on the Risk of Liver-Related Events in Individuals With T2D and MASLD. <i>Clinical Gastroenterology and Hepatology</i> , 2025, 24, 723-732.e10.	6.0	4
35	Attenuation of the second peak of bimodal recurrence of HBV-related HCC after curative treatment in the antiviral era. <i>Journal of Hepatology</i> , 2025, 83, 1328-1337.	4.2	2
36	Impact of first and further decompensation in patients with compensated ACLD due to MASLD. <i>Journal of Hepatology</i> , 2025, 83, 1266-1277.	4.2	1

#	ARTICLE	IF	CITATIONS
37	Recognisable Alcohol Use Significantly Increases the Risk of Adverse Outcomes in Patients With Hepatitis B Virus-Related Cirrhosis. <i>Journal of Viral Hepatitis</i> , 2025, 32, .	2.0	0
38	A Novel Risk Prediction Model for Hepatocellular Carcinoma in MASLD: A Multinational, Multicenter Cohort Study. <i>Clinical Gastroenterology and Hepatology</i> , 2025, , .	6.0	2
39	Longitudinal Changes in Fibrosis Markers: Monitoring Stiffness/Fibrosis Progression and Prognostic Outcomes in MASLD. <i>Clinical Gastroenterology and Hepatology</i> , 2025, 24, 394-406.	6.0	8
40	The Lancet Commission on addressing the global hepatocellular carcinoma burden: comprehensive strategies from prevention to treatment. <i>Lancet, The</i> , 2025, 406, 731-778.	62.3	28
41	Efficacy and safety of ervogastat alone and in combination with clesacostat in patients with biopsy-confirmed metabolic dysfunction-associated steatohepatitis and F2-F3 fibrosis (MIRNA): results from a phase 2, randomised, double-blind, double-dummy study. <i>The Lancet Gastroenterology and Hepatology</i> , 2025, 10, 924-940.	22.9	8
42	Effect of hypertension on long-term adverse clinical outcomes and liver fibrosis progression in MASLD. <i>Journal of Hepatology</i> , 2025, 84, 254-265.	4.2	15
43	Genicriviroc Lacked Efficacy to Treat Liver Fibrosis in Nonalcoholic Steatohepatitis: AURORA Phase III Randomized Study. <i>Clinical Gastroenterology and Hepatology</i> , 2024, 22, 124-134.e1.	6.0	114
44	A multisociety Delphi consensus statement on new fatty liver disease nomenclature. <i>Annals of Hepatology</i> , 2024, 29, 101133.	1.6	457
45	Prevalence and risk factors for impaired renal function among Asian patients with nonalcoholic fatty liver disease. <i>Hepatobiliary and Pancreatic Diseases International</i> , 2024, 23, 241-248.	2.4	8
46	Can we use old NAFLD data under the new MASLD definition?. <i>Journal of Hepatology</i> , 2024, 80, e54-e56.	4.2	287
47	Point-of-Care Noninvasive Prediction of Liver-Related Events in Patients With Nonalcoholic Fatty Liver Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2024, 22, 1637-1645.e9.	6.0	32
48	A randomized, double-blind, placebo-controlled trial of aldafermin in patients with NASH and compensated cirrhosis. <i>Hepatology</i> , 2024, 79, 674-689.	10.1	68
49	Longitudinal Outcomes Associated With Metabolic Dysfunction-Associated Steatotic Liver Disease: A Meta-analysis of 129 Studies. <i>Clinical Gastroenterology and Hepatology</i> , 2024, 22, 488-498.e14.	6.0	89
50	Risk of liver-related events in metabolic dysfunction-associated steatohepatitis (MASH) patients with fibrosis: A comparative analysis of various risk stratification criteria. <i>Hepatology</i> , 2024, 79, 912-925.	10.1	14
51	Diagnosis and assessment of disease severity in patients with nonalcoholic fatty liver disease. <i>United European Gastroenterology Journal</i> , 2024, 12, 219-225.	4.8	9
52	AGA Clinical Practice Update on the Use of Vasoactive Drugs and Intravenous Albumin in Cirrhosis: Expert Review. <i>Gastroenterology</i> , 2024, 166, 202-210.	0.9	45
53	Iron status and non-alcoholic fatty liver disease: A Mendelian randomization study. <i>Nutrition</i> , 2024, 118, 112295.	2.7	4
54	Global survey of stigma among physicians and patients with nonalcoholic fatty liver disease. <i>Journal of Hepatology</i> , 2024, 80, 419-430.	4.2	73

#	ARTICLE	IF	CITATIONS
55	A Liver Stiffness-Based Etiology-Independent Machine Learning Algorithm to Predict Hepatocellular Carcinoma. <i>Clinical Gastroenterology and Hepatology</i> , 2024, 22, 602-610.e7.	6.0	26
56	Long-term use of tenofovir disoproxil fumarate increases fracture risk in elderly patients with chronic hepatitis B. <i>Journal of Hepatology</i> , 2024, 80, 553-563.	4.2	35
57	Machine-learning model comprising five clinical indices and liver stiffness measurement can accurately identify MASLD-related liver fibrosis. <i>Liver International</i> , 2024, 44, 749-759.	3.9	19
58	Implications of the new nomenclature of steatotic liver disease and definition of metabolic dysfunction-associated steatotic liver disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2024, 59, 150-156.	3.7	88
59	Machine learning improves the prediction of significant fibrosis in Asian patients with metabolic dysfunction-associated steatotic liver disease - The Gut and Obesity in Asia (GO-ASIA) Study. <i>Alimentary Pharmacology and Therapeutics</i> , 2024, 59, 774-788.	3.7	17
60	Performance of continuous controlled attenuation parameter and liver stiffness measurement by the novel SmartExam in metabolic dysfunction-associated steatotic liver disease. <i>Liver International</i> , 2024, 44, 1167-1175.	3.9	9
61	Genomic origin, fragmentomics, and transcriptional properties of long cell-free DNA molecules in human plasma. <i>Genome Research</i> , 2024, 34, 189-200.	4.6	15
62	Serum PRO-3 is useful for risk prediction and fibrosis assessment in MAFLD with chronic kidney disease in an Asian cohort. <i>Liver International</i> , 2024, 44, 1129-1141.	3.9	7
63	CAMP score predicts the risk of hepatocellular carcinoma in patients with chronic hepatitis B after HBsAg seroclearance. <i>Alimentary Pharmacology and Therapeutics</i> , 2024, 59, 1223-1235.	3.7	8
64	Vibration-Controlled Transient Elastography Scores to Predict Liver-Related Events in Steatotic Liver Disease. <i>JAMA - Journal of the American Medical Association</i> , 2024, 331, 1287.	16.6	152
65	The impact of stigma on quality of life and liver disease burden among patients with nonalcoholic fatty liver disease. <i>JHEP Reports</i> , 2024, 6, 101066.	4.5	22
66	Diagnostic accuracy of non-invasive tests to screen for at-risk MASH - An individual participant data meta-analysis. <i>Liver International</i> , 2024, 44, 1872-1885.	3.9	15
67	Title is missing!. , 2024, .		0
68	WFUMB Guidelines/Guidance on Liver Multiparametric Ultrasound. Part 2: Guidance on Liver Fat Quantification. <i>Ultrasound in Medicine and Biology</i> , 2024, 50, 1088-1098.	2.0	76
69	WFUMB Guideline/Guidance on Liver Multiparametric Ultrasound: Part 1. Update to 2018 Guidelines on Liver Ultrasound Elastography. <i>Ultrasound in Medicine and Biology</i> , 2024, 50, 1071-1087.	2.0	88
70	EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). <i>Journal of Hepatology</i> , 2024, 81, 492-542.	4.2	1,127
71	A global survey on the use of the international classification of diseases codes for metabolic dysfunction-associated fatty liver disease. <i>Hepatology International</i> , 2024, 18, 1178-1201.	4.2	27
72	MAFLD in adults: non-invasive tests for diagnosis and monitoring of MAFLD. <i>Hepatology International</i> , 2024, 18, 909-921.	4.2	16

#	ARTICLE	IF	CITATIONS
73	A mini-review on prebiotic inulin to prevent and treat non-alcoholic fatty liver disease. <i>Food Bioscience</i> , 2024, 61, 104679.	5.3	6
74	A pilot integrated model nurse clinic increases the uptake of antiviral treatment for the prevention of mother-to-child transmission of HBV. <i>Liver International</i> , 2024, 44, 2583-2591.	3.9	3
75	Diagnosis and non-invasive assessment of MASLD in type 2 diabetes and obesity. <i>Alimentary Pharmacology and Therapeutics</i> , 2024, 59, .	3.7	14
76	Machine Learning-Based Models for Advanced Fibrosis and Cirrhosis Diagnosis in Chronic Hepatitis B Patients With Hepatic Steatosis. <i>Clinical Gastroenterology and Hepatology</i> , 2024, 22, 2250-2260.e12.	6.0	15
77	AI-powered prediction of HCC recurrence after surgical resection: Personalised intervention opportunities using patient-specific risk factors. <i>Liver International</i> , 2024, 44, 2724-2737.	3.9	9
78	Long-term liver-related outcomes and liver stiffness progression of statin usage in steatotic liver disease. <i>Gut</i> , 2024, 73, 1883-1892.	16.8	55
79	Dynamic Changes in ELF Score Predict Hepatocellular Carcinoma in Chronic Hepatitis B Patients Receiving Antiviral Treatment. <i>Journal of Viral Hepatitis</i> , 2024, 31, 808-819.	2.0	0
80	The role of dietary modification in the prevention and management of metabolic dysfunction-associated fatty liver disease: An international multidisciplinary expert consensus. <i>Metabolism: Clinical and Experimental</i> , 2024, 161, 156028.	9.1	85
81	Viral Load-Based Prediction of Hepatocellular Carcinoma Risk in Noncirrhotic Patients With Chronic Hepatitis B. <i>Annals of Internal Medicine</i> , 2024, 177, 1308-1318.	9.7	18
82	Drug-target Mendelian randomisation applied to metabolic dysfunction-associated steatotic liver disease: opportunities and challenges. <i>eGastroenterology</i> , 2024, 2, e100114.	2.6	12
83	Performance of Noninvasive Tests of Fibrosis Among Asians, Hispanic, and non-Hispanic Whites in the STELLAR Trials. <i>Clinical Gastroenterology and Hepatology</i> , 2023, 21, 90-102.e6.	6.0	21
84	Age and the relative importance of liver-related deaths in nonalcoholic fatty liver disease. <i>Hepatology</i> , 2023, 77, 573-584.	10.1	42
85	A Revisit of the Natural History of Nonalcoholic Fatty Liver Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2023, 21, 1152-1153.	6.0	3
86	Real-world evidence on non-invasive tests and associated cut-offs used to assess fibrosis in routine clinical practice. <i>JHEP Reports</i> , 2023, 5, 100596.	4.5	29
87	Liver stiffness thresholds to predict disease progression and clinical outcomes in bridging fibrosis and cirrhosis. <i>Gut</i> , 2023, 72, 581-589.	16.8	81
88	A Meta-analysis on Associated Risk of Mortality in Nonalcoholic Fatty Liver Disease. <i>Endocrine Practice</i> , 2023, 29, 33-39.	3.3	31
89	Comparison of Single Molecule, Real-Time Sequencing and Nanopore Sequencing for Analysis of the Size, End-Motif, and Tissue-of-Origin of Long Cell-Free DNA in Plasma. <i>Clinical Chemistry</i> , 2023, 69, 168-179.	1.1	54
90	Global prevalence of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in the overweight and obese population: a systematic review and meta-analysis. <i>The Lancet Gastroenterology and Hepatology</i> , 2023, 8, 20-30.	22.9	520

#	ARTICLE	IF	CITATIONS
91	Enhanced diagnosis of advanced fibrosis and cirrhosis in individuals with NAFLD using FibroScan-based Agile scores. <i>Journal of Hepatology</i> , 2023, 78, 247-259.	4.2	164
92	Hepatic, Extra-hepatic Outcomes and Causes of Mortality in NAFLD – An Umbrella Overview of Systematic Review of Meta-Analysis. <i>Journal of Clinical and Experimental Hepatology</i> , 2023, 13, 656-665.	2.3	46
93	Risk of hepatic decompensation but not hepatocellular carcinoma decreases over time in patients with hepatitis B surface antigen loss. <i>Journal of Hepatology</i> , 2023, 78, 524-533.	4.2	38
94	Non-invasive biomarkers for liver inflammation in non-alcoholic fatty liver disease: present and future. <i>Clinical and Molecular Hepatology</i> , 2023, 29, S171-S183.	8.9	28
95	Hepatic steatosis and metabolic risk factors among patients with chronic hepatitis B: The multicentre, prospective CAP-Asia study. <i>Journal of Viral Hepatitis</i> , 2023, 30, 319-326.	2.0	9
96	Secondary bile acids improve risk prediction for non-invasive identification of mild liver fibrosis in nonalcoholic fatty liver disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2023, 57, 872-885.	3.7	30
97	CAGE and SAGE models better predict the hepatitis B virus-related hepatocellular carcinoma after 5-year entecavir treatment than PAGE. <i>Journal of Digestive Diseases</i> , 2023, 24, 113-121.	1.6	4
98	Noninvasive Assessment of Liver Fibrosis in NAFLD. <i>Clinical Gastroenterology and Hepatology</i> , 2023, 21, 2026-2039.	6.0	118
99	Nonalcoholic Fatty Liver Disease. <i>Medical Clinics of North America</i> , 2023, 107, 449-463.	3.1	12
100	Diabetes Mellitus Impacts on the Performance of Hepatocellular Carcinoma Risk Scores in Chronic Hepatitis B Patients. <i>Clinical Gastroenterology and Hepatology</i> , 2023, 21, 2864-2875.e16.	6.0	17
101	Trends in risk factor control and treatment among patients with non-alcoholic fatty liver disease and type 2 diabetes between 2000 and 2020: A territory-wide study. <i>Alimentary Pharmacology and Therapeutics</i> , 2023, 57, 1103-1116.	3.7	3
102	Hepatocyte apoptosis fragment product cytokeratin-18 M30 level and non-alcoholic steatohepatitis risk diagnosis: an international registry study. <i>Chinese Medical Journal</i> , 2023, 136, 341-350.	4.4	14
103	The utility of non-invasive tests to assess advanced fibrosis in Asian subjects with chronic hepatitis B and concomitant hepatic steatosis. <i>Liver International</i> , 2023, 43, 1008-1014.	3.9	8
104	The global burden of metabolic disease: Data from 2000 to 2019. <i>Cell Metabolism</i> , 2023, 35, 414-428.e3.	25.2	621
105	Implications of comorbidities in nonalcoholic fatty liver disease. <i>Clinical and Molecular Hepatology</i> , 2023, 29, 384-389.	8.9	2
106	Noninvasive assessment of liver disease severity in patients with nonalcoholic fatty liver disease (NAFLD) and type 2 diabetes. <i>Hepatology</i> , 2023, 78, 195-211.	10.1	41
107	aMAP Score and Its Combination With Liver Stiffness Measurement Accurately Assess Liver Fibrosis in Chronic Hepatitis B Patients. <i>Clinical Gastroenterology and Hepatology</i> , 2023, 21, 3070-3079.e13.	6.0	17
108	Baveno VII Criteria Is an Accurate Risk Stratification Tool to Predict High-Risk Varices Requiring Intervention and Hepatic Events in Patients with Advanced Hepatocellular Carcinoma. <i>Cancers</i> , 2023, 15, 2480.	3.8	13

#	ARTICLE	IF	CITATIONS
109	An international multidisciplinary consensus statement on MAFLD and the risk of CVD. <i>Hepatology International</i> , 2023, 17, 773-791.	4.2	139
110	Changing epidemiology, global trends and implications for outcomes of NAFLD. <i>Journal of Hepatology</i> , 2023, 79, 842-852.	4.2	543
111	Duration of type 2 diabetes and liver-related events in nonalcoholic fatty liver disease: A landmark analysis. <i>Hepatology</i> , 2023, 78, 1816-1827.	10.1	25
112	Impact of fatty liver on long-term outcomes in chronic hepatitis B: a systematic review and matched analysis of individual patient data meta-analysis. <i>Clinical and Molecular Hepatology</i> , 2023, 29, 705-720.	8.9	55
113	Performance of non-invasive tests and histology for the prediction of clinical outcomes in patients with non-alcoholic fatty liver disease: an individual participant data meta-analysis. <i>The Lancet Gastroenterology and Hepatology</i> , 2023, 8, 704-713.	22.9	152
114	Oesophageal varices predict complications in compensated advanced non-alcoholic fatty liver disease. <i>JHEP Reports</i> , 2023, 5, 100809.	4.5	3
115	Baveno VII criteria for recompensation predict transplant-free survival in patients with hepatitis B-related decompensated cirrhosis. <i>JHEP Reports</i> , 2023, 5, 100814.	4.5	23
116	China's Fatty Liver Crisis: A Looming Public Health Emergency. <i>Gastroenterology</i> , 2023, 165, 825-827.	0.9	15
117	A global research priority agenda to advance public health responses to fatty liver disease. <i>Journal of Hepatology</i> , 2023, 79, 618-634.	4.2	103
118	Physical Activity and Nonalcoholic Fatty Liver Disease: A Roundtable Statement from the American College of Sports Medicine. <i>Medicine and Science in Sports and Exercise</i> , 2023, 55, 1717-1726.	0.8	28
119	Risk factors for sessile serrated lesions among Chinese patients undergoing colonoscopy. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2023, 38, 1468-1473.	2.5	5
120	Baveno VII criteria identify varices needing treatment in patients with hepatocellular carcinoma of different Barcelona Clinic Liver Cancer stages. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2023, 38, 1381-1388.	2.5	9
121	Advanced liver fibrosis predicts heart failure and hospitalizations in people with type 2 diabetes: A prospective cohort study from Hong Kong Diabetes Register. <i>Diabetes Research and Clinical Practice</i> , 2023, 202, 110825.	5.9	2
122	Incidence of hepatocellular carcinoma and mortality in chronic viral hepatitis in an Asian population with and without HIV infection. <i>Alimentary Pharmacology and Therapeutics</i> , 2023, 58, 814-823.	3.7	7
123	Clinical care pathway to detect advanced liver disease in patients with type 2 diabetes through automated fibrosis score calculation and electronic reminder messages: a randomised controlled trial. <i>Gut</i> , 2023, 72, 2364-2371.	16.8	38
124	Development, validation, and prognostic evaluation of a risk score for long-term liver-related outcomes in the general population: a multicohort study. <i>Lancet</i> , The, 2023, 402, 988-996.	62.3	119
125	Risk and predictors of hepatic decompensation in grey zone patients by the Baveno VII criteria: A competing risk analysis. <i>Alimentary Pharmacology and Therapeutics</i> , 2023, 58, 920-928.	3.7	19
126	MAFLD fibrosis score: Using routine measures to identify advanced fibrosis in metabolic-associated fatty liver disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2023, 58, 1194-1204.	3.7	19

#	ARTICLE	IF	CITATIONS
127	The silent burden of non-alcoholic fatty liver disease in the elderly: A global burden of disease analysis. <i>Alimentary Pharmacology and Therapeutics</i> , 2023, 58, 1062-1074.	3.7	29
128	Utilization of Food-Derived $\beta$ -Glucans to Prevent and Treat Non-Alcoholic Fatty Liver Disease (NAFLD). <i>Foods</i> , 2023, 12, 3279.	4.6	12
129	FibroScan-aspartate aminotransferase (FAST) score for monitoring histological improvement in non-alcoholic steatohepatitis activity during semaglutide treatment: post-hoc analysis of a randomised, double-blind, placebo-controlled, phase 2b trial. <i>EClinicalMedicine</i> , 2023, 66, 102310.	8.2	27
130	Liver stiffness measurement predicts short-term and long-term outcomes in patients with hepatocellular carcinoma after curative liver resection. <i>Journal of the Royal College of Surgeons of Edinburgh</i> , 2022, 20, 78-84.	2.2	11
131	Microbiota engraftment after faecal microbiota transplantation in obese subjects with type 2 diabetes: a 24-week, double-blind, randomised controlled trial. <i>Gut</i> , 2022, 71, 716-723.	16.8	196
132	Treatment Candidacy for Pharmacologic Therapies for NASH. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 1209-1217.	6.0	35
133	Diagnostic accuracy of non-invasive tests for advanced fibrosis in patients with NAFLD: an individual patient data meta-analysis. <i>Gut</i> , 2022, 71, 1006-1019.	16.8	401
134	A Global Survey of Physicians Knowledge About Nonalcoholic Fatty Liver Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, e1456-e1468.	6.0	98
135	Integrative metabolomic characterisation identifies altered portal vein serum metabolome contributing to human hepatocellular carcinoma. <i>Gut</i> , 2022, 71, 1203-1213.	16.8	108
136	Population screening for liver fibrosis: Toward early diagnosis and intervention for chronic liver diseases. <i>Hepatology</i> , 2022, 75, 219-228.	10.1	241
137	Fatty Pancreas Is Independently Associated With Subsequent Diabetes Mellitus Development: A 10-Year Prospective Cohort Study. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 2014-2022.e4.	6.0	57
138	Asian perspective on NAFLD-associated HCC. <i>Journal of Hepatology</i> , 2022, 76, 726-734.	4.2	127
139	Association of genetic variations with NAFLD in lean individuals. <i>Liver International</i> , 2022, 42, 149-160.	3.9	64
140	Non-obese non-alcoholic fatty liver disease (NAFLD) in Asia: an international registry study. <i>Metabolism: Clinical and Experimental</i> , 2022, 126, 154911.	9.1	47
141	Cirrhosis regression is associated with improved clinical outcomes in patients with nonalcoholic steatohepatitis. <i>Hepatology</i> , 2022, 75, 1235-1246.	10.1	125
142	Clinical and Patient-Reported Outcomes From Patients With Nonalcoholic Fatty Liver Disease Across the World: Data From the Global Non-Alcoholic Steatohepatitis (NASH)/ Non-Alcoholic Fatty Liver Disease (NAFLD) Registry. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 2296-2306.e6.	6.0	88
143	Among simple non-invasive scores, Pro-C3 and ADAPT best exclude advanced fibrosis in Asian patients with MAFLD. <i>Metabolism: Clinical and Experimental</i> , 2022, 128, 154958.	9.1	30
144	Novel machine learning models outperform risk scores in predicting hepatocellular carcinoma in patients with chronic viral hepatitis. <i>JHEP Reports</i> , 2022, 4, 100441.	4.5	41

#	ARTICLE	IF	CITATIONS
145	Liver-related and extrahepatic events in patients with non-alcoholic fatty liver disease: a retrospective competing risks analysis. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 55, 604-615.	3.7	37
146	Non-invasive tests of non-alcoholic fatty liver disease. <i>Chinese Medical Journal</i> , 2022, 135, 532-546.	4.4	44
147	Angiotensin-converting enzyme inhibitors prevent liver-related events in nonalcoholic fatty liver disease. <i>Hepatology</i> , 2022, 76, 469-482.	10.1	77
148	Letter: systematic review with meta-analysis on the impact of functional cure on clinical outcomes in patients with chronic hepatitis B. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 55, 616-617.	3.7	1
149	A cholestatic pattern predicts major liver-related outcomes in patients with non-alcoholic fatty liver disease. <i>Liver International</i> , 2022, 42, 1037-1048.	3.9	11
150	Efficacy and safety of an orally administered DGAT2 inhibitor alone or coadministered with a liver-targeted ACC inhibitor in adults with non-alcoholic steatohepatitis (NASH): rationale and design of the phase II, dose-ranging, dose-finding, randomised, placebo-controlled MIRNA (Metabolic) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 532	1.9	48
151	Risk of liver-related events by age and diabetes duration in patients with diabetes and nonalcoholic fatty liver disease. <i>Hepatology</i> , 2022, 76, 1409-1422.	10.1	47
152	The global NAFLD policy review and preparedness index: Are countries ready to address this silent public health challenge?. <i>Journal of Hepatology</i> , 2022, 76, 771-780.	4.2	219
153	An international survey on patterns of practice in NAFLD and expectations for therapiesâ€”The POPâ€”NEXT project. <i>Hepatology</i> , 2022, 76, 1766-1777.	10.1	14
154	Reliability of the nonalcoholic steatohepatitis clinical research network and steatosis activity fibrosis histological scoring systems. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2022, 37, 1131-1138.	2.5	13
155	Low Accuracy of FIB-4 and NAFLD Fibrosis Scores for Screening for Liver Fibrosis in the Population. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 2567-2576.e6.	6.0	231
156	Nonalcoholic fatty liver disease prevalence and severity in Asian Americans from the national health and nutrition examination surveys 2017â€”2018. <i>Hepatology Communications</i> , 2022, 6, 2253-2261.	4.5	27
157	Tenofovir alafenamide is associated with improved alanine aminotransferase and renal safety compared to tenofovir disoproxil fumarate. <i>Journal of Medical Virology</i> , 2022, 94, 4440-4448.	3.7	10
158	Single-Molecule Sequencing Enables Long Cell-Free DNA Detection and Direct Methylation Analysis for Cancer Patients. <i>Clinical Chemistry</i> , 2022, 68, 1151-1163.	1.1	63
159	Characterization and correction of the effects of hepatic iron on T1 $\rho$ -relaxation in the liver at 3.0T. <i>Magnetic Resonance in Medicine</i> , 2022, 88, 1828-1839.	2.8	7
160	Inhomogeneous liver fibrosis distribution revealed by macromolecular proton fraction quantification based on spin-lock MRI. <i>Quantitative Imaging in Medicine and Surgery</i> , 2022, 12, 4341-4345.	1.4	1
161	Current therapies and new developments in NASH. <i>Gut</i> , 2022, 71, 2123-2134.	16.8	165
162	Universal HBV vaccination dramatically reduces the prevalence of HBV infection and incidence of hepatocellular carcinoma. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 56, 869-877.	3.7	44

#	ARTICLE	IF	CITATIONS
163	Management of NAFLD in primary care settings. <i>Liver International</i> , 2022, 42, 2377-2389.	3.9	70
164	Effectiveness of entecavir vs tenofovir disoproxil fumarate for functional cure of chronic hepatitis B in an international cohort. <i>Hepatology International</i> , 2022, 16, 1297-1307.	4.2	23
165	Risk of HCC in Patients with HBV, Role of Antiviral Treatment. <i>Current Hepatology Reports</i> , 2022, 21, 76-86.	0.6	2
166	N-terminal propeptide of type 3 collagen-based sequential algorithm can identify high-risk steatohepatitis and fibrosis in MAFLD. <i>Hepatology International</i> , 2022, 17, 190-201.	4.2	14
167	Expert Panel Consensus on Clinical Assertion Statements Describing Noninvasive Tools for Diagnosing Nonalcoholic Steatohepatitis. <i>Journal of Clinical Gastroenterology</i> , 2022, 57, 253-264.	2.2	2
168	Letter: vaccination for global control of hepatitis B—from prevention to elimination. Authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 56, 1629-1630.	3.7	0
169	Hepatic Decompensation in Cirrhotic Patients Receiving Antiviral Therapy for Chronic Hepatitis B. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 1950-1958.e7.	6.0	25
170	Impact of the New Definition of Metabolic Associated Fatty Liver Disease on the Epidemiology of the Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 2161-2171.e5.	6.0	147
171	Type 2 Diabetes and Metformin Use Associate With Outcomes of Patients With Nonalcoholic Steatohepatitis-Related, Child-Pugh A Cirrhosis. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 136-145.e6.	6.0	73
172	Monitoring Occurrence of Liver-Related Events and Survival by Transient Elastography in Patients With Nonalcoholic Fatty Liver Disease and Compensated Advanced Chronic Liver Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 806-815.e5.	6.0	162
173	Liver injury is independently associated with adverse clinical outcomes in patients with COVID-19. <i>Gut</i> , 2021, 70, 733-742.	16.8	147
174	Combination Therapies Including Cilofexor and Firsocostat for Bridging Fibrosis and Cirrhosis Attributable to NASH. <i>Hepatology</i> , 2021, 73, 625-643.	10.1	247
175	Significantly Lower Case-fatality Ratio of Coronavirus Disease 2019 (COVID-19) than Severe Acute Respiratory Syndrome (SARS) in Hong Kong—A Territory-Wide Cohort Study. <i>Clinical Infectious Diseases</i> , 2021, 72, e466-e475.	5.2	30
176	ABIDE: An Accurate Predictive Model of Liver Decompensation in Patients With Nonalcoholic Fatty Liver-Related Cirrhosis. <i>Hepatology</i> , 2021, 73, 2238-2250.	10.1	35
177	Negligible HCC risk during stringently defined untreated immune-tolerant phase of chronic hepatitis B. <i>European Journal of Internal Medicine</i> , 2021, 84, 68-73.	2.7	21
178	The Association of Histologic and Noninvasive Tests With Adverse Clinical and Patient-Reported Outcomes in Patients With Advanced Fibrosis Due to Nonalcoholic Steatohepatitis. <i>Gastroenterology</i> , 2021, 160, 1608-1619.e13.	0.9	100
179	Hepatitis Flare During Immunotherapy in Patients With Current or Past Hepatitis B Virus Infection. <i>American Journal of Gastroenterology</i> , 2021, 116, 1274-1283.	0.7	50
180	Risks of AKI and Major Adverse Clinical Outcomes in Patients with Severe Acute Respiratory Syndrome or Coronavirus Disease 2019. <i>Journal of the American Society of Nephrology: JASN</i> , 2021, 32, 961-971.	0.4	19

#	ARTICLE	IF	CITATIONS
181	Implications of Abdominal Adipose Tissue Distribution on Nonalcoholic Fatty Liver Disease and Metabolic Syndrome: A Chinese General Population Study. <i>Clinical and Translational Gastroenterology</i> , 2021, 12, e00300.	2.7	16
182	Clinical Spectrum and Renal Outcome of Cryoglobulinemia in Hong Kong. <i>Kidney360</i> , 2021, 2, 721-728.	1.9	0
183	Aspirin Reduces the Incidence of Hepatocellular Carcinoma in Patients With Chronic Hepatitis B Receiving Oral Nucleos(t)ide Analog. <i>Clinical and Translational Gastroenterology</i> , 2021, 12, e00324.	2.7	26
184	Artificial intelligence in prediction of nonalcoholic fatty liver disease and fibrosis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021, 36, 543-550.	2.5	63
185	Colonoscopy and Risk of Colorectal Cancer in Patients With Nonalcoholic Fatty Liver Disease: A Retrospective Territory-Wide Cohort Study. <i>Hepatology Communications</i> , 2021, 5, 1212-1223.	4.5	13
186	COVID-19 and liver disease: mechanistic and clinical perspectives. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2021, 18, 348-364.	45.8	345
187	Assessment of hepatic steatosis by controlled attenuation parameter using the M and XL probes: an individual patient data meta-analysis. <i>The Lancet Gastroenterology and Hepatology</i> , 2021, 6, 185-198.	22.9	213
188	Simple noninvasive scoring systems and histological scores in predicting mortality in patients with nonalcoholic fatty liver disease: A systematic review and meta-analysis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021, 36, 1754-1768.	2.5	7
189	A prospective 5-year study on the use of transient elastography to monitor the improvement of non-alcoholic fatty liver disease following bariatric surgery. <i>Scientific Reports</i> , 2021, 11, .	3.4	16
190	Reply. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 2684-2685.	6.0	0
191	Negligible risk of hepatocellular carcinoma in chronic hepatitis B patients in immune-tolerant phase: Myth or fact. <i>Clinical and Molecular Hepatology</i> , 2021, 27, 273-277.	8.9	8
192	SARS-CoV-2 Viral Persistence Based on Cycle Threshold Value and Liver Injury in Patients With COVID-19. <i>Open Forum Infectious Diseases</i> , 2021, 8, .	0.8	12
193	Incidences and Determinants of Functional Cure During Entecavir or Tenofovir Disoproxil Fumarate for Chronic Hepatitis B. <i>Journal of Infectious Diseases</i> , 2021, 224, 1890-1899.	3.8	74
194	Improvements of Fibrosis and Disease Activity Are Associated With Improvement of Patient-Reported Outcomes in Patients With Advanced Fibrosis Due to Nonalcoholic Steatohepatitis. <i>Hepatology Communications</i> , 2021, 5, 1201-1211.	4.5	29
195	A Machine Learning Approach Enables Quantitative Measurement of Liver Histology and Disease Monitoring in NASH. <i>Hepatology</i> , 2021, 74, 133-147.	10.1	169
196	Screening for compensated advanced chronic liver disease using refined Baveno VI elastography cutoffs in Asian patients with nonalcoholic fatty liver disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 54, 470-480.	3.7	32
197	Non-alcoholic fatty liver disease. <i>Lancet, The</i> , 2021, 397, 2212-2224.	62.3	2,283
198	Current and Past Infections of HBV Do Not Increase Mortality in Patients With COVID-19. <i>Hepatology</i> , 2021, 74, 1750-1765.	10.1	49

#	ARTICLE	IF	CITATIONS
199	Defining comprehensive models of care for NAFLD. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2021, 18, 717-729.	45.8	119
200	Influence of weight management on the prognosis of steatohepatitis in chronic hepatitis B patients during antiviral treatment. <i>Hepatobiliary and Pancreatic Diseases International</i> , 2021, 20, 416-425.	2.4	15
201	TVB-2640 (FASN Inhibitor) for the Treatment of Nonalcoholic Steatohepatitis: FASCINATE-1, a Randomized, Placebo-Controlled Phase 2a Trial. <i>Gastroenterology</i> , 2021, 161, 1475-1486.	0.9	187
202	Questionnaire survey on knowledge, attitudes, and behaviour towards viral hepatitis among the Hong Kong public. , 2021, , .		6
203	Serum fibrosis index-based risk score predicts hepatocellular carcinoma in untreated patients with chronic hepatitis B. <i>Clinical and Molecular Hepatology</i> , 2021, 27, 499-509.	8.9	16
204	Sodium-glucose co-transporter 2 inhibitors reduce hepatic events in diabetic patients with chronic hepatitis B. <i>GastroHep</i> , 2021, 3, 261-269.	0.8	3
205	Hepatobiliary and Pancreatic: A tree in the liver. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021, 36, 2337-2337.	2.5	1
206	Secular trend of treatment uptake in patients with chronic hepatitis B: A territory-wide study of 135 395 patients from 2000 to 2017. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021, 36, 3487-3499.	2.5	18
207	Association of metformin use on metabolic acidosis in diabetic patients with chronic hepatitis B-related cirrhosis and renal impairment. <i>Health Science Reports</i> , 2021, 4, .	1.6	4
208	Clinical Care Pathway for the Risk Stratification and Management of Patients With Nonalcoholic Fatty Liver Disease. <i>Gastroenterology</i> , 2021, 161, 1657-1669.	0.9	493
209	Quantification of Liver Fat Content with Ultrasound: A WFUMB Position Paper. <i>Ultrasound in Medicine and Biology</i> , 2021, 47, 2803-2820.	2.0	132
210	A Sequential Algorithm Combining ADAPT and Liver Stiffness Can Stage Metabolic-Associated Fatty Liver Disease in Hospital-Based and Primary Care Patients. <i>American Journal of Gastroenterology</i> , 2021, 116, 984-993.	0.7	43
211	Advancing the global public health agenda for NAFLD: a consensus statement. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2021, 19, 60-78.	45.8	608
212	Glucose-lowering drugs and outcome from COVID-19 among patients with type 2 diabetes mellitus: a population-wide analysis in Hong Kong. <i>BMJ Open</i> , 2021, 11, e052310.	1.9	21
213	Similarly low risk of hepatocellular carcinoma after either spontaneous or nucleos(t)ide analogue-induced hepatitis B surface antigen loss. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 53, 321-331.	3.7	30
214	An Aging Population of Chronic Hepatitis B With Increasing Comorbidities: A Territory-Wide Study From 2000 to 2017. <i>Hepatology</i> , 2020, 71, 444-455.	10.1	78
215	Tenofovir Is Associated With Lower Risk of Hepatocellular Carcinoma Than Entecavir in Patients With Chronic HBV Infection in China. <i>Gastroenterology</i> , 2020, 158, 215-225.e6.	0.9	179
216	Quantifying and monitoring fibrosis in non-alcoholic fatty liver disease using dual-photon microscopy. <i>Gut</i> , 2020, 69, 1116-1126.	16.8	40

#	ARTICLE	IF	CITATIONS
217	Reply to Sun et al. <i>Clinical Infectious Diseases</i> , 2020, 70, 2748-2749.	5.2	0
218	Suboptimal treatment of dyslipidemia in patients with nonalcoholic fatty liver disease. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2020, 35, 320-325.	2.5	27
219	Risk of hepatitis B surface antigen seroreversion after corticosteroid treatment in patients with previous hepatitis B virus exposure. <i>Journal of Hepatology</i> , 2020, 72, 57-66.	4.2	71
220	Posttransplant Outcome of Lean Compared With Obese Nonalcoholic Steatohepatitis in the United States: The Obesity Paradox. <i>Liver Transplantation</i> , 2020, 26, 68-79.	2.5	35
221	Development and validation of a model for hepatitis B e antigen seroconversion in entecavir-treated patients with chronic hepatitis B. <i>Journal of Medical Virology</i> , 2020, 92, 1206-1213.	3.7	6
222	Genecriviroc for the treatment of liver fibrosis in adults with nonalcoholic steatohepatitis: AURORA Phase 3 study design. <i>Contemporary Clinical Trials</i> , 2020, 89, 105922.	1.6	120
223	Performance of Simple Fibrosis Scores in Nonobese Patients With Nonalcoholic Fatty Liver Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 2843-2845.e2.	6.0	26
224	The safety of stopping nucleos(t)ide analogue treatment in patients with HBeAg-negative chronic hepatitis B. <i>Liver International</i> , 2020, 40, 549-557.	3.9	20
225	Reassessing the accuracy of PAGE-B-related scores to predict hepatocellular carcinoma development in patients with chronic hepatitis B. <i>Journal of Hepatology</i> , 2020, 72, 847-854.	4.2	63
226	Liver stiffness measurement predicts long-term survival and complications in nonalcoholic fatty liver disease. <i>Liver International</i> , 2020, 40, 581-589.	3.9	107
227	ALT Levels for Asians With Metabolic Diseases: A Meta-analysis of 86 Studies With Individual Patient Data Validation. <i>Hepatology Communications</i> , 2020, 4, 1624-1636.	4.5	25
228	Pattern and impact of hepatic adverse events encountered during immune checkpoint inhibitors – A territory-wide cohort study. <i>Cancer Medicine</i> , 2020, 9, 7052-7061.	2.6	23
229	Management of patients with liver derangement during the COVID-19 pandemic: an Asia-Pacific position statement. <i>The Lancet Gastroenterology and Hepatology</i> , 2020, 5, 776-787.	22.9	91
230	East Asia expert opinion on treatment initiation for chronic hepatitis B. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 1540-1550.	3.7	65
231	Fatigue and Pruritus in Patients with Advanced Fibrosis Due to Nonalcoholic Steatohepatitis: The Impact on Patient-Reported Outcomes. <i>Hepatology Communications</i> , 2020, 4, 1637-1650.	4.5	51
232	Unhealthy lifestyle habits and physical inactivity among Asian patients with nonalcoholic fatty liver disease. <i>Liver International</i> , 2020, 40, 2719-2731.	3.9	49
233	Increasing antiviral treatment uptake improves survival in patients with HBV-related HCC. <i>JHEP Reports</i> , 2020, 2, 100152.	4.5	31
234	Elevated testosterone increases risk of hepatocellular carcinoma in men with chronic hepatitis B and diabetes mellitus. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2020, 35, 2210-2219.	2.5	25

#	ARTICLE	IF	CITATIONS
235	Epidemiology of nonalcoholic fatty liver disease in non-obese populations: Meta-analytic assessment of its prevalence, genetic, metabolic, and histological profiles. <i>Journal of Digestive Diseases</i> , 2020, 21, 372-384.	1.6	41
236	SGLT2 Inhibitors in Liver Patients. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 2168-2172.e2.	6.0	43
237	Modelling the economic and clinical burden of non-alcoholic steatohepatitis in East Asia: Data from Hong Kong. <i>Hepatology Research</i> , 2020, 50, 1024-1031.	2.9	44
238	Positive Hepatitis B Core Antibody Is Associated With Cirrhosis and Hepatocellular Carcinoma in Nonalcoholic Fatty Liver Disease. <i>American Journal of Gastroenterology</i> , 2020, 115, 867-875.	0.7	51
239	Serum hepatitis B core-related antigen predicts hepatocellular carcinoma in hepatitis B e antigen-negative patients. <i>Journal of Gastroenterology</i> , 2020, 55, 899-908.	4.1	27
240	Ethnic influence on nonalcoholic fatty liver disease prevalence and lack of disease awareness in the United States, 2011-2016. <i>Journal of Internal Medicine</i> , 2020, 287, 711-722.	7.3	76
241	Modelling NAFLD disease burden in four Asian regions-2019-2030. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 51, 801-811.	3.7	143
242	Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: Results from randomized phase III STELLAR trials. <i>Journal of Hepatology</i> , 2020, 73, 26-39.	4.2	419
243	Endoscopic ultrasound-guided cyanoacrylate injection to prevent rebleeding in hepatocellular carcinoma patients with variceal hemorrhage. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2020, 35, 2192-2201.	2.5	5
244	Macromolecular proton fraction mapping based on spin-locked magnetic resonance imaging. <i>Magnetic Resonance in Medicine</i> , 2020, 84, 3157-3171.	2.8	12
245	Factors associated with improvement in MELD score after antiviral treatment in patients with chronic hepatitis B. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2020, 35, 1610-1618.	2.5	6
246	Cilofexor, a Nonsteroidal FXR Agonist, in Patients With Noncirrhotic NASH: A Phase 2 Randomized Controlled Trial. <i>Hepatology</i> , 2020, 72, 58-71.	10.1	303
247	MAFLD: A Consensus-Driven Proposed Nomenclature for Metabolic Associated Fatty Liver Disease. <i>Gastroenterology</i> , 2020, 158, 1999-2014.e1.	0.9	2,797
248	Cenicriviroc Treatment for Adults With Nonalcoholic Steatohepatitis and Fibrosis: Final Analysis of the Phase 2b CENTAUR Study. <i>Hepatology</i> , 2020, 72, 892-905.	10.1	331
249	Serial Transient Elastography Examinations to Monitor Patients With Type 2 Diabetes: A Prospective Cohort Study. <i>Hepatology</i> , 2020, 72, 1230-1241.	10.1	76
250	FibroScan-AST (FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: a prospective derivation and global validation study. <i>The Lancet Gastroenterology and Hepatology</i> , 2020, 5, 362-373.	22.9	681
251	Association Between Fibrosis Stage and Outcomes of Patients With Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis. <i>Gastroenterology</i> , 2020, 158, 1611-1625.e12.	0.9	895
252	High incidence of hepatocellular carcinoma and cirrhotic complications in patients with psychiatric illness: a territory-wide cohort study. <i>BMC Gastroenterology</i> , 2020, 20, .	2.2	8

#	ARTICLE	IF	CITATIONS
253	Predictors of advanced fibrosis in elderly patients with biopsy-confirmed nonalcoholic fatty liver disease: the GOASIA study. <i>BMC Gastroenterology</i> , 2020, 20, .	2.2	42
254	A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement. <i>Journal of Hepatology</i> , 2020, 73, 202-209.	4.2	3,642
255	Thiazolidinediones reduce the risk of hepatocellular carcinoma and hepatic events in diabetic patients with chronic hepatitis B. <i>Journal of Viral Hepatitis</i> , 2020, 27, 904-914.	2.0	20
256	Use of hepatitis B virus core-related antigen to evaluate natural history of chronic hepatitis B. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2020, 35, 2202-2209.	2.5	9
257	Confounding factors of non-invasive tests for nonalcoholic fatty liver disease. <i>Journal of Gastroenterology</i> , 2020, 55, 731-741.	4.1	32
258	Application of transient elastography in nonalcoholic fatty liver disease. <i>Clinical and Molecular Hepatology</i> , 2020, 26, 128-141.	8.9	108
259	Gamma-glutamyl transferase and cardiovascular risk in nonalcoholic fatty liver disease: The Gut and Obesity Asia initiative. <i>World Journal of Gastroenterology</i> , 2020, 26, 2415-2425.	0.0	0
260	Letter: elevated aspartate aminotransferase and aspartate aminotransferase to alanine aminotransferase ratio predicts poor survival in hepatocellular carcinoma after resection—Authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 1764-1764.	3.7	0
261	Repeating measurements by transient elastography in non-alcoholic fatty liver disease patients with high liver stiffness. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2019, 34, 241-248.	2.5	35
262	Optimizing Use of Nonalcoholic Fatty Liver Disease Fibrosis Score, Fibrosis-4 Score, and Liver Stiffness Measurement to Identify Patients With Advanced Fibrosis. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 2570-2580.e37.	6.0	90
263	Noninvasive Tests Accurately Identify Advanced Fibrosis due to NASH: Baseline Data From the STELLAR Trials. <i>Hepatology</i> , 2019, 70, 1521-1530.	10.1	247
264	THU-237-Increasing prevalence of indications to choose bone/renal-friendly antiviral drug: A territory-wide study of 135,414 patients from 2000 to 2017. <i>Journal of Hepatology</i> , 2019, 70, e269.	4.2	0
265	Tenofovir disoproxil fumarate reduces hepatocellular carcinoma, decompensation and death in chronic hepatitis B patients with cirrhosis. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 50, 1037-1048.	3.7	73
266	Transient elastography for screening of liver fibrosis: Cost-effectiveness analysis from six prospective cohorts in Europe and Asia. <i>Journal of Hepatology</i> , 2019, 71, 1141-1151.	4.2	139
267	Unified interpretation of liver stiffness measurement by M and XL probes in non-alcoholic fatty liver disease. <i>Gut</i> , 2019, 68, 2057-2064.	16.8	156
268	Low Risk of Variceal Bleeding in Patients With Cirrhosis After Variceal Screening Stratified by Liver/Spleen Stiffness. <i>Hepatology</i> , 2019, 70, 971-981.	10.1	41
269	Change in treatment paradigm in people who previously injected drugs with chronic hepatitis C in the era of direct-acting antiviral therapy. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2019, 34, 1641-1647.	2.5	14
270	Reduced Patient-Reported Outcome Scores Associate With Level of Fibrosis in Patients With Nonalcoholic Steatohepatitis. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 2552-2560.e10.	6.0	79

#	ARTICLE	IF	CITATIONS
271	Improvement in enhanced liver fibrosis score and liver stiffness measurement reflects lower risk of hepatocellular carcinoma. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 49, 1509-1517.	3.7	22
272	Prevalence, incidence, and outcome of non-alcoholic fatty liver disease in Asia, 1999â€“2019: a systematic review and meta-analysis. <i>The Lancet Gastroenterology and Hepatology</i> , 2019, 4, 389-398.	22.9	888
273	Genome-wide Association Study Identifies Genetic Variants Associated With Early and Sustained Response to (Pegylated) Interferon in Chronic Hepatitis B Patients: The GIANT-B Study. <i>Clinical Infectious Diseases</i> , 2019, 69, 1969-1979.	5.2	27
274	Effects of Alcohol Consumption and Metabolic Syndrome on Mortality in Patients With Nonalcoholic and Alcohol-Related Fatty Liver Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 1625-1633.e1.	6.0	156
275	Magnitude of Nonalcoholic Fatty Liver Disease: Eastern Perspective. <i>Journal of Clinical and Experimental Hepatology</i> , 2019, 9, 491-496.	2.3	16
276	Machine learning model to predict recurrent ulcer bleeding in patients with history of idiopathic gastroduodenal ulcer bleeding. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 49, 912-918.	3.7	51
277	Patients With Nonalcoholic Steatohepatitis Experience Severe Impairment of Health-Related Quality of Life. <i>American Journal of Gastroenterology</i> , 2019, 114, 1636-1641.	0.7	48
278	Impact of Obesity and Alanine Aminotransferase Levels on the Diagnostic Accuracy for Advanced Liver Fibrosis of Noninvasive Tools in Patients With Nonalcoholic Fatty Liver Disease. <i>American Journal of Gastroenterology</i> , 2019, 114, 916-928.	0.7	87
279	Impact of dose and duration of corticosteroid on the risk of hepatitis flare in patients with chronic hepatitis B. <i>Liver International</i> , 2019, 39, 271-279.	3.9	32
280	Global Perspectives on Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis. <i>Hepatology</i> , 2019, 69, 2672-2682.	10.1	1,628
281	Clinical outcomes and management of patients with chronic hepatitis B and liver stiffness measurement in the grey zone. <i>Liver International</i> , 2019, 39, 494-502.	3.9	9
282	HBsAg seroclearance further reduces hepatocellular carcinoma risk after complete viral suppression with nucleos(t)ide analogues. <i>Journal of Hepatology</i> , 2019, 70, 361-370.	4.2	269
283	Association of Pretransplant Renal Function With Liver Graft and Patient Survival After Liver Transplantation in Patients With Nonalcoholic Steatohepatitis. <i>Liver Transplantation</i> , 2019, 25, 399-410.	2.5	31
284	Can the same controlled attenuation parameter cutâ€“offs be used for M and XL probes for diagnosing hepatic steatosis?. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2018, 33, 1787-1794.	2.5	48
285	Impact of controlled attenuation parameter on detecting fibrosis using liver stiffness measurement. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 47, 989-1000.	3.7	50
286	Clinical features and treatment of nonalcoholic fatty liver disease across the Asia Pacific regionâ€“the GO ASIA initiative. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 47, 816-825.	3.7	65
287	Review article: longâ€“term safety of oral antiâ€“viral treatment for chronic hepatitis B. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 47, 730-737.	3.7	73
288	Effects of Diabetes and Glycemic Control on Risk of Hepatocellular Carcinoma After Seroclearance of Hepatitis B Surface Antigen. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 765-773.e2.	6.0	58

#	ARTICLE	IF	CITATIONS
289	Chronic Hepatitis B Increases Liver-Related Mortality of Patients With Acute Hepatitis E: A Territorywide Cohort Study From 2000 to 2016. <i>Clinical Infectious Diseases</i> , 2018, 67, 1278-1284.	5.2	45
290	Development of a scoring system to predict hepatocellular carcinoma in Asians on antivirals for chronic hepatitis B. <i>Journal of Hepatology</i> , 2018, 69, 278-285.	4.2	159
291	Asia-Pacific Working Party on Non-alcoholic Fatty Liver Disease guidelines 2017 Part 1: Definition, risk factors and assessment. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2018, 33, 70-85.	2.5	430
292	The Asia-Pacific Working Party on Non-alcoholic Fatty Liver Disease guidelines 2017 Part 2: Management and special groups. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2018, 33, 86-98.	2.5	152
293	Impact of diabetes mellitus and hepatitis B virus coinfection on patients with chronic hepatitis C: A territorywide cohort study. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2018, 33, 934-941.	2.5	11
294	Durability of hepatitis B surface antigen seroclearance in untreated and nucleos(t)ide analogue-treated patients. <i>Journal of Hepatology</i> , 2018, 68, 63-72.	4.2	98
295	Advanced liver fibrosis but not steatosis is independently associated with albuminuria in Chinese patients with type 2 diabetes. <i>Journal of Hepatology</i> , 2018, 68, 147-156.	4.2	77
296	Poor adherence to hepatocellular carcinoma surveillance: A systematic review and meta-analysis of a complex issue. <i>Liver International</i> , 2018, 38, 503-514.	3.9	81
297	A randomized, placebo-controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosis. <i>Hepatology</i> , 2018, 67, 1754-1767.	10.1	599
298	Four-year Outcomes After Cessation of Tenofovir in Immune-tolerant Chronic Hepatitis B Patients. <i>Journal of Clinical Gastroenterology</i> , 2018, 52, 347-352.	2.2	26
299	An inflammatory-CCRK circuitry drives mTORC1-dependent metabolic and immunosuppressive reprogramming in obesity-associated hepatocellular carcinoma. <i>Nature Communications</i> , 2018, 9, .	13.7	83
300	Letter: chronic kidney disease risk in patients with chronic hepatitis B authors reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 48, 1324-1324.	3.7	0
301	On-Treatment Improvement of MELD Score Reduces Death and Hepatic Events in Patients With Hepatitis B-Related Cirrhosis. <i>American Journal of Gastroenterology</i> , 2018, 113, 1629-1638.	0.7	25
302	Normal on-treatment ALT during antiviral treatment is associated with a lower risk of hepatic events in patients with chronic hepatitis B. <i>Journal of Hepatology</i> , 2018, 69, 793-802.	4.2	96
303	Liver Ultrasound Elastography: An Update to the World Federation for Ultrasound in Medicine and Biology Guidelines and Recommendations. <i>Ultrasound in Medicine and Biology</i> , 2018, 44, 2419-2440.	2.0	494
304	Noninvasive biomarkers in NAFLD and NASH current progress and future promise. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2018, 15, 461-478.	45.8	540
305	Non-invasive prediction of esophageal varices by stiffness and platelet in non-alcoholic fatty liver disease cirrhosis. <i>Journal of Hepatology</i> , 2018, 69, 878-885.	4.2	131
306	Systematic review with meta-analysis: Change in liver stiffness during anti-viral therapy in patients with hepatitis B. <i>Digestive and Liver Disease</i> , 2018, 50, 787-794.	2.5	29

#	ARTICLE	IF	CITATIONS
307	Fibrosis Severity as a Determinant of Cause-Specific Mortality in Patients With Advanced Nonalcoholic Fatty Liver Disease: A Multi-National Cohort Study. <i>Gastroenterology</i> , 2018, 155, 443-457.e17.	0.9	718
308	Territory-wide population-based study of chronic hepatitis C infection and implications for hepatitis elimination in Hong Kong. <i>Liver International</i> , 2018, 38, 1911-1919.	3.9	17
309	Beneficial effects of lifestyle intervention in non-obese patients with non-alcoholic fatty liver disease. <i>Journal of Hepatology</i> , 2018, 69, 1349-1356.	4.2	280
310	Chronic kidney disease progression in patients with chronic hepatitis B on tenofovir, entecavir, or no treatment. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 48, 984-992.	3.7	67
311	Metagenomic analysis of faecal microbiome as a tool towards targeted non-invasive biomarkers for colorectal cancer. <i>Gut</i> , 2017, 66, 70-78.	16.8	1,130
312	Controlled attenuation parameter using the FibroScan® XL probe for quantification of hepatic steatosis for non-alcoholic fatty liver disease in an Asian population. <i>United European Gastroenterology Journal</i> , 2017, 5, 76-85.	4.8	78
313	Histological severity and clinical outcomes of nonalcoholic fatty liver disease in nonobese patients. <i>Hepatology</i> , 2017, 65, 54-64.	10.1	312
314	Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: Systematic review and meta-analysis. <i>Hepatology</i> , 2017, 65, 1557-1565.	10.1	1,674
315	Diagnostic Accuracy of Noninvasive Fibrosis Scores in a Population of Individuals With a Low Prevalence of Fibrosis. <i>Clinical Gastroenterology and Hepatology</i> , 2017, 15, 1453-1460.e1.	6.0	50
316	Long-term use of oral nucleos(t)ide analogues for chronic hepatitis B does not increase cancer risk – a cohort study of 44 494 subjects. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 45, 1213-1224.	3.7	25
317	Mechanism and prediction of HCC development in HBV infection. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2017, 31, 291-298.	2.7	28
318	Significant positive association of endotoxemia with histological severity in 237 patients with non-alcoholic fatty liver disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 46, 175-182.	3.7	74
319	HCV Genotype 6 Increased the Risk for Hepatocellular Carcinoma Among Asian Patients With Liver Cirrhosis. <i>American Journal of Gastroenterology</i> , 2017, 112, 1111-1119.	0.7	46
320	Cost-effectiveness of the highly effective direct-acting antivirals in the treatment of chronic hepatitis C in Hong Kong. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2017, 32, 1071-1078.	2.5	7
321	Validity criteria for the diagnosis of fatty liver by M probe-based controlled attenuation parameter. <i>Journal of Hepatology</i> , 2017, 67, 577-584.	4.2	136
322	New trends on obesity and NAFLD in Asia. <i>Journal of Hepatology</i> , 2017, 67, 862-873.	4.2	976
323	Laboratory parameter-based machine learning model for excluding non-alcoholic fatty liver disease (NAFLD) in the general population. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 46, 447-456.	3.7	172
324	International incidence and mortality trends of liver cancer: a global profile. <i>Scientific Reports</i> , 2017, 7, .	3.4	215

#	ARTICLE	IF	CITATIONS
325	Individual patient data meta-analysis of controlled attenuation parameter (CAP) technology for assessing steatosis. <i>Journal of Hepatology</i> , 2017, 66, 1022-1030.	4.2	1,071
326	Application of the combined FibroMeter vibration-controlled transient elastography algorithm in Chinese patients with non-alcoholic fatty liver disease. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2017, 32, 1363-1369.	2.5	54
327	Prognostic Value of Controlled Attenuation Parameter by Transient Elastography. <i>American Journal of Gastroenterology</i> , 2017, 112, 1812-1823.	0.7	78
328	Statins reduce the risk of liver decompensation and death in chronic viral hepatitis: a propensity score weighted landmark analysis. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 46, 1001-1010.	3.7	58
329	Serial combination of non-invasive tools improves the diagnostic accuracy of severe liver fibrosis in patients with NAFLD. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 46, 617-627.	3.7	156
330	Managing HCC in NAFLD. <i>Current Hepatology Reports</i> , 2017, 16, 374-381.	0.6	3
331	Impact of age and gender on risk of hepatocellular carcinoma after hepatitis B surface antigen seroclearance. <i>Journal of Hepatology</i> , 2017, 67, 902-908.	4.2	138
332	The role of quantitative hepatitis B surface antigen revisited. <i>Journal of Hepatology</i> , 2017, 66, 398-411.	4.2	317
333	Real-life efficacy and safety of paritaprevir/ritonavir, ombitasvir, and dasabuvir in chronic hepatitis C patients in Hong Kong. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2017, 32, 1230-1233.	2.5	16
334	Improved noninvasive prediction of liver fibrosis by liver stiffness measurement in patients with nonalcoholic fatty liver disease accounting for controlled attenuation parameter values. <i>Hepatology</i> , 2017, 65, 1145-1155.	10.1	203
335	Liver stiffness measurement predicts high-grade post-hepatectomy liver failure: A prospective cohort study. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2017, 32, 506-514.	2.5	43
336	Utility and Safety of Tolvaptan in Cirrhotic Patients with Hyponatremia: a Prospective Cohort Study. <i>Annals of Hepatology</i> , 2017, 16, 123-132.	1.6	13
337	Invasive and non-invasive assessment of portal hypertension. <i>Hepatology International</i> , 2017, 12, 44-55.	4.2	55
338	Measuring spleen stiffness to predict varices in chronic hepatitis B cirrhotic patients with or without receiving non-selective beta-blockers. <i>Journal of Digestive Diseases</i> , 2016, 17, 538-546.	1.6	32
339	Controlled attenuation parameter for the diagnosis of steatosis in non-alcoholic fatty liver disease. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2016, 31, 848-855.	2.5	168
340	Long-term clinical outcomes after fatty liver screening in patients undergoing coronary angiogram: A prospective cohort study. <i>Hepatology</i> , 2016, 63, 754-763.	10.1	127
341	Prevalence of hepatitis B and clinical outcomes in inflammatory bowel disease patients in a viral-endemic region. <i>BMC Gastroenterology</i> , 2016, 16, .	2.2	12
342	Letter: is HIV infection an important factor for liver fibrosis? Authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2016, 44, 1002-1003.	3.7	0

#	ARTICLE	IF	CITATIONS
343	Virus and Host Testing to Manage Chronic Hepatitis B. <i>Clinical Infectious Diseases</i> , 2016, 62, S298-S305.	5.2	14
344	Metabolic syndrome increases cardiovascular events but not hepatic events and death in patients with chronic hepatitis B. <i>Hepatology</i> , 2016, 64, 1507-1517.	10.1	27
345	Pathogenesis and novel treatment options for non-alcoholic steatohepatitis. <i>The Lancet Gastroenterology and Hepatology</i> , 2016, 1, 56-67.	22.9	171
346	In search of new biomarkers for nonalcoholic fatty liver disease. <i>Clinical Liver Disease</i> , 2016, 8, 19-23.	1.3	10
347	Real-world risk score for hepatocellular carcinoma (RWS-HCC): a clinically practical risk predictor for HCC in chronic hepatitis B. <i>Gut</i> , 2016, 65, 887-888.	16.8	49
348	Sofosbuvir plus ribavirin for the treatment of patients with chronic genotype 1 or 6 hepatitis C virus infection in Hong Kong. <i>Alimentary Pharmacology and Therapeutics</i> , 2016, 43, 96-101.	3.7	26
349	Screening diabetic patients for non-alcoholic fatty liver disease with controlled attenuation parameter and liver stiffness measurements: a prospective cohort study. <i>Gut</i> , 2016, 65, 1359-1368.	16.8	439
350	Nonalcoholic fatty liver disease. <i>Nature Reviews Disease Primers</i> , 2015, 1, .	47.2	760
351	Long-term safety of oral nucleos(t)ide analogs for patients with chronic hepatitis B: A cohort study of 53,500 subjects. <i>Hepatology</i> , 2015, 62, 684-693.	10.1	88
352	Can we use HCC risk scores to individualize surveillance in chronic hepatitis B infection?. <i>Journal of Hepatology</i> , 2015, 63, 722-732.	4.2	110
353	Letter: association between moderate alcohol consumption and non-alcoholic fatty liver disease - authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2015, 42, 1331-1332.	3.7	0
354	Adverse Effects of Vitamin D Deficiency on Outcomes of Patients With Chronic Hepatitis B. <i>Clinical Gastroenterology and Hepatology</i> , 2015, 13, 783-790.e1.	6.0	58
355	Impact of IL28B and PNPLA3 polymorphisms on treatment outcomes in patients infected with genotype 6 hepatitis C virus. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2015, 30, 1040-1048.	2.5	7
356	Lengthening and shortening of plasma DNA in hepatocellular carcinoma patients. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, .	7.5	653
357	PNPLA3 gene polymorphism and response to lifestyle modification in patients with nonalcoholic fatty liver disease. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2015, 30, 139-146.	2.5	147
358	Probability-Based Interpretation of Liver Stiffness Measurement in Untreated Chronic Hepatitis B Patients. <i>Digestive Diseases and Sciences</i> , 2015, 60, 1448-1456.	2.1	19
359	Treatment cessation of entecavir in Asian patients with hepatitis B e antigen negative chronic hepatitis B: a multicentre prospective study. <i>Gut</i> , 2015, 64, 667-672.	16.8	204
360	Prevalence and Severity of Nonalcoholic Fatty Liver Disease in Non-Obese Patients: A Population Study Using Proton-Magnetic Resonance Spectroscopy. <i>American Journal of Gastroenterology</i> , 2015, 110, 1306-1314.	0.7	276

#	ARTICLE	IF	CITATIONS
361	Statin and the risk of hepatocellular carcinoma and death in a hospital-based hepatitis B-infected population: A propensity score landmark analysis. <i>Journal of Hepatology</i> , 2015, 63, 1190-1197.	4.2	94
362	Truncated HBxâ€dependent silencing of GAS2 promotes hepatocarcinogenesis through deregulation of cell cycle, senescence and p53â€mediated apoptosis. <i>Journal of Pathology</i> , 2015, 237, 38-49.	4.9	35
363	Incidence of non-alcoholic fatty liver disease in Hong Kong: A population study with paired proton-magnetic resonance spectroscopy. <i>Journal of Hepatology</i> , 2015, 62, 182-189.	4.2	157
364	Histone Deacetylase 8 Is a Novel Chromatin Modulator in NAFLD-Associated Hepatocarcinogenesis. <i>Clinical Gastroenterology and Hepatology</i> , 2015, 13, 219.	6.0	2
365	Cost Effectiveness of Response-Guided Therapy With Peginterferon in the Treatment of Chronic Hepatitis B. <i>Clinical Gastroenterology and Hepatology</i> , 2015, 13, 377-385.e5.	6.0	12
366	Noninvasive assessments of liver fibrosis with transient elastography and <sc>H</sc>ui index predict survival in patients with chronic hepatitis <sc>B</sc>. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2015, 30, 582-590.	2.5	13
367	Higher Estimated Net Endogenous Acid Production May Be Associated with Increased Prevalence of Nonalcoholic Fatty Liver Disease in Chinese Adults in Hong Kong. <i>PLoS ONE</i> , 2015, 10, e0122406.	2.3	33
368	Diet-Quality Scores and Prevalence of Nonalcoholic Fatty Liver Disease: A Population Study Using Proton-Magnetic Resonance Spectroscopy. <i>PLoS ONE</i> , 2015, 10, e0139310.	2.3	95
369	Oneâ€stop clinic for ketamineâ€associated uropathy: report on service delivery model, patients' characteristics and nonâ€invasive investigations at baseline by a crossâ€sectional study in a prospective cohort of 318 teenagers and young adults. <i>BJU International</i> , 2014, 114, 754-760.	3.2	48
370	Targeted hepatitis C screening among exâ€injection drug users in the community. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2014, 29, 116-120.	2.5	29
371	Prevalence of the TM6SF2 variant and non-alcoholic fatty liver disease in Chinese. <i>Journal of Hepatology</i> , 2014, 61, 708-709.	4.2	73
372	Liver stiffness-based optimization of hepatocellular carcinoma risk score in patients with chronic hepatitis B. <i>Journal of Hepatology</i> , 2014, 60, 339-345.	4.2	259
373	Fatty Pancreas, Insulin Resistance, and Î²-Cell Function: A Population Study Using Fat-Water Magnetic Resonance Imaging. <i>American Journal of Gastroenterology</i> , 2014, 109, 589-597.	0.7	245
374	Liver Injury Is Common Among Chronic Abusers of Ketamine. <i>Clinical Gastroenterology and Hepatology</i> , 2014, 12, 1759-1762.e1.	6.0	68
375	Non-alcoholic fatty liver disease: Spectral patterns observed from an in vivo phosphorus magnetic resonance spectroscopy study. <i>Journal of Hepatology</i> , 2014, 60, 809-815.	4.2	37
376	Tertiary Prevention of HBV-related HCC in Asia. <i>Current Hepatitis Reports</i> , 2013, 12, 157-164.	1.0	1
377	Epigenetic regulation of hepatocellular carcinoma in non-alcoholic fatty liver disease. <i>Seminars in Cancer Biology</i> , 2013, 23, 471-482.	13.7	95
378	Association Between Anthropometric Parameters and Measurements of Liver Stiffness by Transient Elastography. <i>Clinical Gastroenterology and Hepatology</i> , 2013, 11, 295-302.e3.	6.0	73

#	ARTICLE	IF	CITATIONS
379	Liver fibrosis progression is uncommon in patients with inactive chronic hepatitis B: A prospective cohort study with paired transient elastography examination. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2013, 28, 1842-1848.	2.5	40
380	Treatment of non-alcoholic steatohepatitis with <i>Phyllanthus urinaria</i> : A randomized trial. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2013, 28, 57-62.	2.5	27
381	Letter: diagnostic accuracy of M30 levels for identifying patients with non-alcoholic steatohepatitis – authors’ reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2013, 37, 283-284.	3.7	0
382	Entecavir treatment reduces hepatic events and deaths in chronic hepatitis B patients With liver cirrhosis. <i>Hepatology</i> , 2013, 58, 1537-1547.	10.1	450
383	Accuracy of Risk Scores for Patients With Chronic Hepatitis B Receiving Entecavir Treatment. <i>Gastroenterology</i> , 2013, 144, 933-944.	0.9	161
384	Nonalcoholic fatty liver disease in Asia: A story of growth. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2013, 28, 18-23.	2.5	65
385	Community-based lifestyle modification programme for non-alcoholic fatty liver disease: A randomized controlled trial. <i>Journal of Hepatology</i> , 2013, 59, 536-542.	4.2	306
386	NAFLD in Asia – as common and important as in the West. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2013, 10, 307-318.	45.8	415
387	Quantitative Elastography of Liver Fibrosis and Spleen Stiffness in Chronic Hepatitis B Carriers: Comparison of Shear-Wave Elastography and Transient Elastography with Liver Biopsy Correlation. <i>Radiology</i> , 2013, 269, 910-918.	8.7	291
388	Liver fibrosis progression in chronic hepatitis B patients positive for hepatitis B e antigen: A prospective cohort study with paired transient elastography examination. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2013, 28, 1762-1769.	2.5	24
389	Chronic Hepatitis B: A Treatment Update. <i>Seminars in Liver Disease</i> , 2013, 33, 122-129.	3.2	14
390	Consolidation therapy for HBeAg-positive Asian chronic hepatitis B patients receiving lamivudine treatment: a multicentre study. <i>Journal of Antimicrobial Chemotherapy</i> , 2013, , .	3.1	17
391	Serum Hepatitis B Surface Antigen Kinetics in Severe Reactivation of Hepatitis B E Antigen Negative Chronic Hepatitis B Patients Receiving Nucleoside/Nucleotide Analogues. <i>Antiviral Therapy</i> , 2013, 18, 979-986.	1.9	13
392	Liver Stiffness Measurement by Transient Elastography as a Predictor on Posthepatectomy Outcomes. <i>Annals of Surgery</i> , 2013, 257, 922-928.	4.6	106
393	Efficacy of Entecavir Switch Therapy in Chronic Hepatitis B Patients with Incomplete Virological Response to Telbivudine. <i>Antiviral Therapy</i> , 2013, 18, 671-680.	1.9	8
394	Molecular Characterization of the Fecal Microbiota in Patients with Nonalcoholic Steatohepatitis – A Longitudinal Study. <i>PLoS ONE</i> , 2013, 8, e62885.	2.3	295
395	Non-invasive assessment of liver fibrosis with transient elastography (FibroScan®): applying the cut-offs of M probe to XL probe. <i>Annals of Hepatology</i> , 2013, 12, 402-412.	1.6	32
396	Treatment of nonalcoholic steatohepatitis with probiotics. A proof-of-concept study. <i>Annals of Hepatology</i> , 2013, 12, 256-262.	1.6	296

#	ARTICLE	IF	CITATIONS
397	Prevalence of non-alcoholic fatty liver disease and advanced fibrosis in Hong Kong Chinese: a population study using proton-magnetic resonance spectroscopy and transient elastography. <i>Gut</i> , 2012, 61, 409-415.	16.8	466
398	Diagnosis and personalized management of hepatitis B including significance of genotypes. <i>Current Opinion in Infectious Diseases</i> , 2012, 25, 570-577.	3.4	15
399	Liver Stiffness Measurement Using XL Probe in Patients With Nonalcoholic Fatty Liver Disease. <i>American Journal of Gastroenterology</i> , 2012, 107, 1862-1871.	0.7	316
400	Hepatitis B virus infection and fatty liver in the general population. <i>Journal of Hepatology</i> , 2012, 56, 533-540.	4.2	217
401	Diagnosis of liver fibrosis and cirrhosis using liver stiffness measurement: Comparison between M and XL probe of FibroScan®. <i>Journal of Hepatology</i> , 2012, 56, 833-839.	4.2	230
402	Non-invasive diagnosis of non-alcoholic steatohepatitis by combined serum biomarkers. <i>Journal of Hepatology</i> , 2012, 56, 1363-1370.	4.2	223
403	Polymorphisms Near IL28B and Serologic Response to Peginterferon in HBeAg-Positive Patients With Chronic Hepatitis B. <i>Gastroenterology</i> , 2012, 142, 513-520.e1.	0.9	172
404	Endoscopic Pancreatic Necrosectomy: Notes of Excitement. <i>Gastroenterology</i> , 2012, 143, 1114-1115.	0.9	0
405	A randomized comparison of ultrathin and standard colonoscope in cecal intubation rate and patient tolerance. <i>Gastrointestinal Endoscopy</i> , 2012, 75, 484-490.	1.8	22
406	Prevention of hepatocellular carcinoma: a concise review of contemporary issues. <i>Annals of Hepatology</i> , 2012, 11, 284-293.	1.6	22
407	606: Maternal HBeAg status and hepatitis B viral activity in HBsAg positive mothers. <i>American Journal of Obstetrics and Gynecology</i> , 2012, 206, S273.	2.4	0
408	High prevalence of colorectal neoplasm in patients with non-alcoholic steatohepatitis. <i>Gut</i> , 2011, 60, 829-836.	16.8	237
409	Entecavir treatment in patients with severe acute exacerbation of chronic hepatitis B. <i>Journal of Hepatology</i> , 2011, 54, 236-242.	4.2	125
410	Is transient elastography inaccurate in chronic hepatitis B and non-alcoholic fatty liver disease?. <i>Journal of Hepatology</i> , 2011, 55, 497.	4.2	6
411	Risk estimation for hepatocellular carcinoma in chronic hepatitis B (REACH-B): development and validation of a predictive score. <i>Lancet Oncology</i> , The, 2011, 12, 568-574.	27.4	620
412	On-Treatment Monitoring of Liver Fibrosis with Transient Elastography in Chronic Hepatitis B Patients. <i>Antiviral Therapy</i> , 2011, 16, 165-172.	1.9	92
413	Prediction of off-Treatment Response to Lamivudine by Serum Hepatitis B Surface Antigen Quantification in Hepatitis B E Antigen-Negative Patients. <i>Antiviral Therapy</i> , 2011, 16, 1249-1257.	1.9	107
414	Factors associated with unreliable liver stiffness measurement and its failure with transient elastography in the Chinese population. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2011, 26, 300-305.	2.5	135

#	ARTICLE	IF	CITATIONS
415	Nonalcoholic fatty liver in Asia: Firmly entrenched and rapidly gaining ground. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2011, 26, 163-172.	2.5	138
416	Should all patients with nonalcoholic fatty liver disease undergo oral glucose tolerance test?. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2011, 26, 419-420.	2.5	4
417	Do we need a histological score to diagnose non-alcoholic steatohepatitis?. <i>Alimentary Pharmacology and Therapeutics</i> , 2011, 34, 494-495.	3.7	3
418	Application of transient elastography in chronic hepatitis B. <i>Alimentary Pharmacology and Therapeutics</i> , 2011, 34, 817-818.	3.7	3
419	The effect of caffeine and alcohol consumption on liver fibrosis - a study of 1045 Asian hepatitis B patients using transient elastography. <i>Liver International</i> , 2011, 31, 1047-1053.	3.9	37
420	Coronary artery disease and cardiovascular outcomes in patients with non-alcoholic fatty liver disease. <i>Gut</i> , 2011, 60, 1721-1727.	16.8	272
421	Viral Determinants of Hepatitis B Surface Antigen Seroclearance in Hepatitis B e Antigen-“Negative Chronic Hepatitis B Patients. <i>Journal of Infectious Diseases</i> , 2011, 204, 408-414.	3.8	118
422	Antiviral Drug Resistance Testing in Patients with Chronic Hepatitis B. <i>Digestive Diseases and Sciences</i> , 2011, 57, 221-231.	2.1	7
423	Carboxyl-Terminal Truncated HBx Regulates a Distinct MicroRNA Transcription Program in Hepatocellular Carcinoma Development. <i>PLoS ONE</i> , 2011, 6, e22888.	2.3	77
424	Cost-effectiveness analysis of roadmap models in chronic hepatitis B using tenofovir as the rescue therapy. <i>Antiviral Therapy</i> , 2010, 15, 145-155.	1.9	38
425	Continuation of Low-Dose Aspirin Therapy in Peptic Ulcer Bleeding. <i>Annals of Internal Medicine</i> , 2010, 152, 1-9.	9.7	417
426	Impact of Antiviral Therapy on Risk of Hepatocellular Carcinoma. <i>Current Hepatitis Reports</i> , 2010, 9, 47-52.	1.0	0
427	Rate and Factors Affecting Treatment Uptake of Patients with Chronic Hepatitis C in a Tertiary Referral Hospital. <i>Digestive Diseases and Sciences</i> , 2010, 55, 3541-3547.	2.1	19
428	Diagnosis of fibrosis and cirrhosis using liver stiffness measurement in nonalcoholic fatty liver disease. <i>Hepatology</i> , 2010, 51, 454-462.	10.1	1,174
429	Durability of Peginterferon Alfa-2B Treatment at 5 Years in Patients With Hepatitis B E Antigen-“Positive Chronic Hepatitis B. <i>Hepatology</i> , 2010, 51, 1945-1953.	10.1	105
430	A Longitudinal Study on the Natural History of Serum Hepatitis B Surface Antigen Changes in Chronic Hepatitis B. <i>Hepatology</i> , 2010, 52, 1232-1241.	10.1	235
431	Transient elastography. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2010, 25, 1726-1731.	2.5	85
432	Disease progression of non-alcoholic fatty liver disease: a prospective study with paired liver biopsies at 3-...years. <i>Gut</i> , 2010, 59, 969-974.	16.8	580

#	ARTICLE	IF	CITATIONS
433	Hepatitis B Virus (HBV) Subgenotypes C2 and B2 Differ in Lamivudine- and Adefovir-Resistance-Associated Mutational Patterns in HBV-Infected Chinese Patients. <i>Journal of Clinical Microbiology</i> , 2010, 48, 4363-4369.	4.0	37
434	Metabolic syndrome and chronic hepatitis B: is the evidence enough?. <i>Gut</i> , 2010, 59, 277.1-277.	16.8	0
435	Interaction of Adipokines and Hepatitis B Virus on Histological Liver Injury in the Chinese. <i>American Journal of Gastroenterology</i> , 2010, 105, 132-138.	0.7	65
436	Authors' response: Table 1. <i>Gut</i> , 2010, 59, 559-560.	16.8	0
437	Reactivation of hepatitis B virus infection with persistently negative HBsAg on three HBsAg assays in a lymphoma patient undergoing chemotherapy. <i>Journal of Clinical Virology</i> , 2010, 47, 193-195.	3.0	17
438	Association of hepatitis B virus mutations in basal core promoter and precore regions with severity of liver disease: an investigation of 793 Chinese patients with mild and severe chronic hepatitis B and acute-on-chronic liver failure. <i>Journal of Gastroenterology</i> , 2010, 46, 391-400.	4.1	66
439	Bacterial Microbiota Profiling in Gastritis without <i>Helicobacter pylori</i> Infection or Non-Steroidal Anti-Inflammatory Drug Use. <i>PLoS ONE</i> , 2009, 4, e7985.	2.3	222
440	Long-term Follow-up of Ulcerative Colitis in the Chinese Population. <i>American Journal of Gastroenterology</i> , 2009, 104, 647-654.	0.7	93
441	Evaluation of Impact of Serial Hepatitis B Virus DNA Levels on Development of Hepatocellular Carcinoma. <i>Journal of Clinical Microbiology</i> , 2009, 47, 1830-1836.	4.0	23
442	Antiviral therapy for chronic hepatitis B: are we doing any good to patients?. <i>Journal of Antimicrobial Chemotherapy</i> , 2009, 64, 223-226.	3.1	2
443	High serum interleukin-6 level predicts future hepatocellular carcinoma development in patients with chronic hepatitis B. <i>International Journal of Cancer</i> , 2009, 124, 2766-2770.	4.3	203
444	Cyclooxygenase-2 inhibitors in patients with high gastrointestinal risk: are we there yet?. <i>Journal of Gastroenterology</i> , 2009, 44, 53-56.	4.1	4
445	Evaluation of Model for End Stage Liver Disease (MELD)-based systems as prognostic index for hepatocellular carcinoma. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2009, 24, 63-69.	2.5	24
446	Increased liver stiffness measurement by transient elastography in severe acute exacerbation of chronic hepatitis B. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2009, 24, 1002-1007.	2.5	112
447	Interferon-induced thyroid dysfunction not always transient. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2009, 24, 938-940.	2.5	5
448	Severe acute exacerbation of chronic hepatitis B: A unique presentation of a common disease. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2009, 24, 1179-1186.	2.5	69
449	Surrogate End Points and Long-Term Outcome in Patients With Chronic Hepatitis B. <i>Clinical Gastroenterology and Hepatology</i> , 2009, 7, 1113-1120.	6.0	47
450	High Incidence of Mortality and Recurrent Bleeding in Patients With <i>Helicobacter pylori</i> -Negative Idiopathic Bleeding Ulcers. <i>Gastroenterology</i> , 2009, 137, 525-531.	0.9	134

#	ARTICLE	IF	CITATIONS
451	Clinical Factors Associated With Liver Stiffness in Hepatitis B e Antigen-Positive Chronic Hepatitis B Patients. <i>Clinical Gastroenterology and Hepatology</i> , 2009, 7, 227-233.	6.0	77
452	921 IS THE ROADMAP MODEL COST-EFFECTIVE IN THE ERA OF TENOFOVIR IN THE TREATMENT OF CHRONIC HEPATITIS B VIRUS (HBV) INFECTION?. <i>Journal of Hepatology</i> , 2009, 50, S335.	4.2	0
453	Predicting Mortality in Patients With Bleeding Peptic Ulcers After Therapeutic Endoscopy. <i>Clinical Gastroenterology and Hepatology</i> , 2009, 7, 311-316.	6.0	93
454	Hepatitis B Virus Genotype C Is Associated With More Severe Liver Fibrosis Than Genotype B. <i>Clinical Gastroenterology and Hepatology</i> , 2009, 7, 1361-1366.	6.0	77
455	A review of the natural history of chronic hepatitis B in the era of transient elastography. <i>Antiviral Therapy</i> , 2009, 14, 489-499.	1.9	35
456	Phyllanthus urinaria ameliorates the severity of nutritional steatohepatitis both in vitro and in vivo. <i>Hepatology</i> , 2008, 47, 473-483.	10.1	41
457	Surveillance programme for hepatocellular carcinoma improves the survival of patients with chronic viral hepatitis. <i>Liver International</i> , 2008, 28, 79-87.	3.9	109
458	Health-related quality of life in Chinese patients with primary biliary cirrhosis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2008, 23, 592-598.	2.5	16
459	Association of cytokine gene polymorphisms and liver fibrosis in chronic hepatitis B. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2008, 23, 783-789.	2.5	23
460	Genetic polymorphisms of adiponectin and tumor necrosis factor- $\alpha$ and nonalcoholic fatty liver disease in Chinese people. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2008, 23, 914-921.	2.5	61
461	A complete genomic analysis of hepatitis B virus genotypes and mutations in HBeAg-negative chronic hepatitis B in China. <i>Journal of Viral Hepatitis</i> , 2008, 15, 449-458.	2.0	14
462	Early Hepatitis B Virus DNA Suppression Can Predict Virologic Response to Peginterferon and Lamivudine Treatment. <i>Clinical Gastroenterology and Hepatology</i> , 2008, 6, 1022-1026.	6.0	25
463	Assessment of Fibrosis by Transient Elastography Compared With Liver Biopsy and Morphometry in Chronic Liver Diseases. <i>Clinical Gastroenterology and Hepatology</i> , 2008, 6, 1027-1035.	6.0	147
464	Validation of the NAFLD Fibrosis Score in a Chinese Population With Low Prevalence of Advanced Fibrosis. <i>American Journal of Gastroenterology</i> , 2008, , ???-???	0.7	105
465	Evaluation of Alanine Transaminase and Hepatitis B Virus DNA to Predict Liver Cirrhosis in Hepatitis B e Antigen-Negative Chronic Hepatitis B Using Transient Elastography. <i>American Journal of Gastroenterology</i> , 2008, 103, 3071-3081.	0.7	85
466	High Viral Load and Hepatitis B Virus Subgenotype Ce Are Associated With Increased Risk of Hepatocellular Carcinoma. <i>Journal of Clinical Oncology</i> , 2008, 26, 177-182.	16.9	288
467	Hepatocyte growth factor promotes proliferation and migration in immortalized progenitor cells. <i>NeuroReport</i> , 2008, 19, 765-769.	1.5	19
468	Long-Term follow-up of Lamivudine Treatment in Patients with Severe Acute Exacerbation of Hepatitis B e Antigen (HBeAg)-Positive Chronic Hepatitis B. <i>Antiviral Therapy</i> , 2008, 13, 571-579.	1.9	33

#	ARTICLE	IF	CITATIONS
469	Treatment of Patients with Chronic Hepatitis B who have Failed Previous Antiviral Treatment with Pegylated Interferon $\hat{1}\pm 2a$ (40 kDa; PEGASYS $\hat{A}$ $\text{\textcircled{R}}$ ). <i>Antiviral Therapy</i> , 2008, 13, 555-562.	1.9	12
470	Virodynamic Predictors of Response to Pegylated Interferon and Lamivudine Combination Treatment of Hepatitis B e Antigen-Positive Chronic Hepatitis B. <i>Antiviral Therapy</i> , 2008, 13, 1029-1037.	1.9	3
471	Initial Treatment With Lansoprazole in Young Dyspeptic Patients With Negative Urea Breath Test Result: A Randomized Controlled Trial With 12-Month Follow-Up. <i>American Journal of Gastroenterology</i> , 2007, 102, 1483-1488.	0.7	11
472	Small bowel enteropathy associated with chronic low-dose aspirin therapy. <i>Lancet, The</i> , 2007, 369, 614.	62.3	48
473	Serum Hepatitis B Surface Antigen Quantitation Can Reflect Hepatitis B Virus in the Liver and Predict Treatment Response. <i>Clinical Gastroenterology and Hepatology</i> , 2007, 5, 1462-1468.	6.0	331
474	Distinct Clinical Characteristics Between Patients With Nonerosive Reflux Disease and Those With Reflux Esophagitis. <i>Clinical Gastroenterology and Hepatology</i> , 2007, 5, 690-695.	6.0	102
475	Performance of the new MELD-Na score in predicting 3-month and 1-year mortality in chinese patients with chronic hepatitis B. <i>Liver Transplantation</i> , 2007, 13, 1228-1235.	2.5	56
476	Can dietetic intervention for obesity ever succeed in real life?. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2007, 22, 459-460.	2.5	4
477	Virtual colonoscopy-induced perforation in a patient with Crohn $\hat{A}$ $\text{\textcircled{R}}$ s disease. <i>World Journal of Gastroenterology</i> , 2007, 13, 978.	0.0	18
478	Virological Response to Different Combination Regimes of Peginterferon $\hat{1}\pm 2b$ and Lamivudine in Hepatitis B e Antigen Positive Chronic Hepatitis B. <i>Antiviral Therapy</i> , 2007, 12, 815-823.	1.9	29
479	Metabolic and Adipokine Profile of Chinese Patients With Nonalcoholic Fatty Liver Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2006, 4, 1154-1161.	6.0	186
480	Expression profilings of 39 genes selected by ANOVA could separate precursors of murine dendritic cells and macrophages. <i>Biochemical and Biophysical Research Communications</i> , 2006, 344, 438-445.	2.1	0
481	Genetic polymorphisms of interleukin-1-beta in association with sustained response to anti-viral treatment in chronic hepatitis B in Chinese. <i>Alimentary Pharmacology and Therapeutics</i> , 2006, 23, 1703-1711.	3.7	15
482	Evaluation of Model for End-Stage Liver Disease for Prediction of Mortality in Decompensated Chronic Hepatitis B. <i>American Journal of Gastroenterology</i> , 2006, 101, 1516-1523.	0.7	59
483	Long-Term Lamivudine Treatment is Associated with a Good Maintained Response in Severe Acute Exacerbation of Chronic Hbeag-Negative Hepatitis B. <i>Antiviral Therapy</i> , 2006, 11, 465-471.	1.9	28
484	Long-term follow-up of peginterferon and lamivudine combination treatment in HBeAg-positive chronic hepatitis B. <i>Hepatology</i> , 2005, 41, 1357-1364.	10.1	77
485	Molecular virology and drug resistance in antiviral therapy of chronic hepatitis B. <i>Current Hepatitis Reports</i> , 2005, 4, 27-33.	1.0	0
486	A Randomized, Controlled Trial of Combination Therapy for Chronic Hepatitis B: Comparing Pegylated Interferon- $\hat{1}\pm 2b$ and Lamivudine with Lamivudine Alone. <i>Annals of Internal Medicine</i> , 2005, 142, 240-250.	9.7	248

#	ARTICLE	IF	CITATIONS
487	Identification of Chronic Hepatitis B Patients without Significant Liver Fibrosis by a Simple Noninvasive Predictive Model. <i>American Journal of Gastroenterology</i> , 2005, 100, 616-623.	0.7	207
488	A hospital clinic-based survey on traditional Chinese medicine usage among chronic hepatitis B patients. <i>Complementary Therapies in Medicine</i> , 2005, 13, 175-182.	3.0	29
489	A Retrospective Study on Clinical Features and Prognostic Factors of Biopsy-Proven Primary Biliary Cirrhosis in Chinese Patients. <i>American Journal of Gastroenterology</i> , 2005, 100, 2205-2211.	0.7	30
490	Clinical course after stopping lamivudine in chronic hepatitis B patients with lamivudine-resistant mutants. <i>Alimentary Pharmacology and Therapeutics</i> , 2004, 19, 323-329.	3.7	25
491	Celecoxib versus diclofenac plus omeprazole in high-risk arthritis patients: Results of a randomized double-blind trial. <i>Gastroenterology</i> , 2004, 127, 1038-1043.	0.9	146
492	Upper gastrointestinal complications related to non-steroidal anti-inflammatory drugs—what have we achieved so far?. <i>Digestive and Liver Disease</i> , 2004, 36, 1-3.	2.5	4
493	A cirrhotic patient with fever and abdominal pain in the presence of ascites. <i>British Journal of Hospital Medicine</i> , 2003, 64, 310-310.	0.2	1
494	Hepatocellular carcinoma surveillance after HBsAg seroclearance. , 0, , 175-189.		0
495	ALADDIN: A Machine Learning Approach to Enhance the Prediction of Significant Fibrosis or Higher in Metabolic Dysfunction-Associated Steatotic Liver Disease. <i>American Journal of Gastroenterology</i> , 0, 121, 362-374.	0.7	5
496	Increased risk of HCC in HBeAg-negative indeterminate phase compared with HBeAg-negative chronic infection. <i>Hepatology</i> , 0, 83, 156-168.	10.1	5
497	Non-invasive risk-based surveillance of hepatocellular carcinoma in patients with metabolic dysfunction-associated steatotic liver disease. <i>Gut</i> , 0, 74, 2050-2057.	16.8	14
498	Non-invasive tests of fibrosis in the management of MASLD: revolutionising diagnosis, progression and regression monitoring. <i>Gut</i> , 0, 74, 1741-1750.	16.8	5
499	Quantitative macromolecular proton fraction imaging using pulsed spin-echo. <i>Magnetic Resonance in Medicine</i> , 0, 94, 2492-2507.	2.8	1
500	Dynamics of Cardiometabolic Risk Factors Are Linked to the Risk of Hypertension and Diabetes in MASLD. <i>Kaohsiung Journal of Medical Sciences</i> , 0, 41, .	2.6	1
501	Broadening PEth testing for alcohol exposure in the Asia-Pacific region. <i>Journal of Hepatology</i> , 0, 83, e229-e231.	4.2	2
502	Foundations of Artificial Intelligence in Hepatology: What a Clinician Needs to Know?. <i>Journal of Clinical and Experimental Hepatology</i> , 0, 16, 103183.	2.3	0
503	Comparative Risk of Hepatitis B Virus Reactivation in Patients Receiving Immune Checkpoint Inhibitors or Tyrosine Kinase Inhibitors for Liver Cancer. <i>Alimentary Pharmacology and Therapeutics</i> , 0, 63, 383-395.	3.7	6
504	Projected Global Clinical, Humanistic, and Economic Impact of Metabolic Dysfunction-Associated Steatohepatitis (MASH): The Cost of Inaction Based on Data From Nine Countries. <i>Clinical Gastroenterology and Hepatology</i> , 0, , .	6.0	3

#	ARTICLE	IF	CITATIONS
505	Managing <scp>MASLD</scp> Through Preventive Hepatology: Integrating Policy Reform, Public Health and Personalised Care. <i>Liver International</i> , 0, 45, .	3.9	3
506	Clinical trial design, biomarkers and end points in metabolic and alcohol-related liver disease. <i>Nature Reviews Gastroenterology and Hepatology</i> , 0, 22, 866-884.	45.8	4
507	Long-Term Glycemic Control and the Risk of Liver Stiffness Progression and Liver-Related Events in MASLD. <i>Clinical Gastroenterology and Hepatology</i> , 0, , .	6.0	4
508	Global performance of non-invasive tests in MASLD: Insights from the G-MASLD study. <i>Hepatology</i> , 0, , .	10.1	1
509	Exploration of Multiple Non-Invasive Tests for Assessing Response to Treatment in a Semaglutide Phase 2b Trial in Patients with <scp>MASH</scp>. <i>Alimentary Pharmacology and Therapeutics</i> , 0, 63, 396-404.	3.7	1
510	Association between longitudinal weight change and clinical outcome in individuals with MASLD. <i>Hepatology</i> , 0, , .	10.1	4
511	Validation of a data-driven clustering model for MASLD: Evidence from three large-scale Asian cohorts. <i>JHEP Reports</i> , 0, 8, 101645.	4.5	1
512	Histological severity and hepatic outcomes in patients with metabolic dysfunction-associated steatotic liver disease and discrepant FIB-4 and liver stiffness measurement. <i>Clinical and Molecular Hepatology</i> , 0, 32, 289-304.	8.9	0
513	Expert Delphi Consensus on Surrogate Endpoints for Treatment Assessment in Metabolic Dysfunction-associated Steatohepatitis. <i>Clinical Gastroenterology and Hepatology</i> , 0, , .	6.0	0
514	Fibrotic MASH resolutionVCTE index to diagnose fibrotic MASH resolution and predict LREs: A global multicenter study. <i>Med</i> , 0, , 100929.	7.0	0
515	Head-to-head comparison between vibration-controlled transient elastography and histology in predicting liver-related events due to metabolic dysfunction-associated steatotic liver disease. <i>Hepatology</i> , 0, , .	10.1	0
516	Colorectal cancer in metabolic dysfunction-associated steatotic liver disease: an international Delphi consensus statement. <i>Gut</i> , 0, , gutjnl-2025-337374.	16.8	0
517	Two-step clinical care pathway to predict MASLD-related advanced fibrosis and long-term outcomes in type 2 diabetes. <i>Gut</i> , 0, 75, 576-587.	16.8	0
518	Challenges in defining MASLD in lean individuals: the impact of the Fatty Liver Index on phenotypic characterisation. <i>Gut</i> , 0, , gutjnl-2026-338216.	16.8	0